Future Directions in Osteoporosis Therapeutics

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 3, 2012, Pages 655-661

  Bone, Henry ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Anabolic agents; Antiresorptives; Osteocytes; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CATHEPSIN K; CATHEPSIN K INHIBITOR; DENOSUMAB; ESTROGEN; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PROTEIN INHIBITOR; SALCATONIN; SCLEROSTIN;

BONE DENSITY; BONE REMODELING; BONE STRENGTH; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HORMONAL THERAPY; HUMAN; JAW OSTEONECROSIS; LONG TERM CARE; MAINTENANCE THERAPY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAIN; POSTMENOPAUSE OSTEOPOROSIS; PREVENTION STUDY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT PLANNING; WNT SIGNALING PATHWAY;

AGED; AGED, 80 AND OVER; ANABOLIC AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OSTEOPOROSIS, POSTMENOPAUSAL; PHARMACOLOGY, CLINICAL; RANK LIGAND;

EID: 84864808754     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.05.003     Document Type: Review

References (31)

1. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(10):1479-1491.
2. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25(11):2267-2294.
3. Rittmaster R.S., Bolognese M., Ettinger M.P., et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85(6):2129-2134.
4. Black D.M., Bilezikian J.P., Ensrud K.E., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353(6):555-565.
5. Binkley N., Bolognese M., Sidorowicz-Bialynicka A., et al. A phase 3 trial of the efficacy and safety or oral recombinant calcitonin: the ORACAL trial. J Bone Miner Res 2012, 10.1002/jbmr.1602.
6. Knopp-Sihota J.A., Newburn-Cook C.V., Homik J., et al. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int 2012, 23(1):17-38.
7. Bone H.G., Greenspan S.L., McKeever C., et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000, 85(2):720-726.
8. Greenspan S.L., Resnick N.M., Parker R.A. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003, 289(19):2525-2533.
9. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 88(3):321-333.
10. North American Menopause Society The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause 2012, 19(3):257-271.
11. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297(13):1465-1477.
12. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291(14):1701-1712.
13. Stevenson J.C. A woman's journey through the reproductive, transitional and postmenopausal periods of life: impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement. Maturitas 2011, 70(2):197-205.
14. Lindsay R., Hart D.M., Aitken J.M., et al. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976, 1(7968):1038-1041.
15. Lufkin E.G., Wahner H.W., O'Fallon W.M., et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992, 117(1):1-9.
16. Lane N.E., Sanchez S., Modin G.W., et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102(8):1627-1633.
17. Lindsay R., Nieves J., Formica C., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350(9077):550-555.
18. Stolina M., Kostenuik P.J., Dougall W.C., et al. RANKL inhibition: from mice to men (and women). Adv Exp Med Biol 2007, 602:143-150.
19. Papapoulos S., Chapurlat R., Libanati C., et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012, [Epub ahead of print]. 10.1002/jbmr.1479.
20. Cummings S.R., San Martin J., McClung M.R., et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-765. [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914].
21. Rünger T.M., Adami S., Benhamou C.L., et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 2012, 66(3):e89-e96.
22. Bone H.G., McClung M.R., Roux C., et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010, 25(5):937-947.
23. Eisman J.A., Bone H.G., Hosking D.J., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011, 26(2):242-251. 10.1002/jbmr.212.
24. Costa A.G., Cusano N.E., Silva B.C., et al. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 2011, 7(8):447-456. 10.1038/nrrheum.2011.77.
25. Binkley N, Bone H, Gilchrist N, et al. Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial. Presented at the American Society of Bone & Mineral Research Meeting. San Diego, September 16-20, 2011.
26. Fitzpatrick L.A., Dabrowski C.E., Cicconetti G., et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2011, 96(8):2441-2449.
27. Frost H.M. Treatment of osteoporosis by manipulation of coherent bone cell populations. Clin Orthop Relat Res 1979, (143):227-244.
28. Bonewald L.F. The amazing osteocyte. J Bone Miner Res 2011, 26(2):229-238. 10.1002/jbmr.320.
29. Frost H.M. The mechanostat: a proposed pathogenic mechanism of osteoporosis and the bone mass effects of mechanical and nonmechanical agents. Bone Miner 1987, 2(2):73-85.
30. Davison K.S., Siminoski K., Adachi J.D., et al. Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum 2006, 36(1):22-31.
31. Turner C.H. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002, 13(2):97-104.